Skip to content

Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV Infection

A Phase III Trial to Determine the Efficacy of Bivalent AIDSVAX B/B Vaccine in Adults at Risk of Sexually Transmitted HIV-1 Infection in North America

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00002441
Enrollment
5000
Registered
2001-08-31
Start date
Unknown
Completion date
Unknown
Last updated
2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections, HIV Seronegativity

Keywords

HIV-1, Dose-Response Relationship, Drug, Acquired Immunodeficiency Syndrome, AIDS Vaccines, Sexually Transmitted Diseases, Risk Factors, HIV Seronegativity, Antigens, Viral, Alum Compounds

Brief summary

The purpose of this study is to see if an HIV vaccine, AIDSVAX B/B, can protect adults who are at risk from becoming infected with HIV. Patients who become infected despite immunization will be studied to see if receiving the vaccine before becoming infected will help keep HIV levels (viral load) low.

Detailed description

Volunteers receive 7 blinded, intramuscular vaccinations (at Months 0, 1, 6, 12, 18, 24, 30) containing either the AIDSVAX B/B vaccine or a placebo (aluminum adjuvant only). Volunteers are randomized in a 2 to 1 vaccine-to-placebo ratio. HIV-uninfected persons are followed for a total of 16 visits beginning at screening and continuing until Month 36. Patients who become HIV infected during study are followed every 4 months for at least 24 months.

Interventions

Sponsors

VaxGen
Lead SponsorINDUSTRY

Study design

Primary purpose
PREVENTION
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Exclusion criteria

You will not be eligible for this study if you: * Use injection drugs. * Have a history of any serious diseases or conditions, including lymphoma. * Have ever received an HIV vaccine. * Have taken post-exposure treatment to prevent HIV infection within 4 weeks prior to study entry. * Are planning to take other HIV vaccines during this study. * Are pregnant. * Have taken certain medications or received certain therapies, including chemotherapy and radiation. * Have received certain vaccines within 2-4 weeks prior to study entry. You may be eligible for this study if you: * Are HIV-negative. * Are between 18 and 60 years old. * Are available for 3 years of follow-up. * Agree to use effective methods of birth control during the study and for 90 days after. * Are one of the following: * A woman who is currently in a sexual relationship with an HIV-positive man. * A woman who has had more than one male partner and at least one sexually transmitted disease (STD) within the past 12 months. * A man who has sex with men and has had anal intercourse within the past 12 months. (You will not be eligible if you have been in the same relationship with only one HIV-negative man for at least 12 months.)

Countries

Canada, Netherlands, Puerto Rico, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026